Monitor for the final pricing supplement to determine share count, price, and net proceeds. The dilutive raise for a going-concern clinical-stage company with negative book value is a clear negative signal. Watch for potential downward pressure on NRXP common stock and NRXPW warrants as the market prices in dilution.
Price Chart
Executive Summary
NRx Pharmaceuticals filed a preliminary prospectus supplement for an underwritten firm-commitment common stock offering under its existing $150M shelf registration. All key terms (share count, price, net proceeds) are placeholder TBD values, but the offering represents a dilutive capital raise for a clinical-stage biopharma with negative tangible book value (-$0.46/share as of March 31, 2026) and a going-concern audit opinion. The stock closed at $4.62 on June 1, 2026.
Key Facts
- Preliminary prospectus supplement for an underwritten common stock offering; all dollar/share amounts are placeholder TBD values.
- Underwriters: BTIG (lead bookrunner) and Lucid Capital Markets (joint bookrunner); firm-commitment basis with 30-day over-allotment option.
- As of March 31, 2026, net tangible book value was approximately -$16,488,000, or -$0.46 per share.
- 36,228,992 shares outstanding as of May 15, 2026; excludes 687,490 options (weighted avg exercise $8.62), 9,359,710 warrants (weighted avg $7.77), and 32,895 restricted stock awards.
- Audited financial statements include going-concern explanatory paragraphs from both Weinberg & Company and Salberg & Company.
- Proceeds intended for working capital and general corporate purposes; management retains broad discretion.
- 60-day lock-up agreements with officers, directors, and the company.
- Cross-filing context: S-3/A filed Dec 12, 2025 registered up to $150M in securities; this 424B5 is a takedown from that shelf.
Financial Impact
Offering size and price are undisclosed (TBD placeholders). Based on the $150M shelf and the company's negative tangible book value of -$16.5M, the offering could be material relative to current market cap. Dilution to existing shareholders is expected.
Risk Factors
- Dilution to existing shareholders from new share issuance.
- Going-concern risk highlighted in audited financial statements.
- Clinical-stage company with no approved products and negative tangible book value.
- Potential for further dilutive offerings given the broad shelf registration.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001437749-26-019194 |
| Document: 0001437749-26-019194-index-headers.html | 0001437749-26-019194 |
| Document: 0001437749-26-019194-index.html | 0001437749-26-019194 |
| Document: 0001437749-26-019194.txt | 0001437749-26-019194 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 4, 2026 17w ago | 8-K | โ | awaiting T+5 | โ | โ |
Jun 3, 2026 17w ago | 424B5 | โ | awaiting T+5 | โ | โ |
Jun 2, 2026 17w ago | 424B5 | โ | awaiting T+5 | โ | โ |
May 22, 2026 19w ago | 25-NSE | $0.0142 $0.0142 | ยท 0.00% | โฒ +1.21% | โ |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access